Acorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled for October 31, 2017
October 10 2017 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference
call and webcast to report its third quarter 2017 financial results
and pipeline updates on Tuesday, October 31 at 8:30 a.m.
ET.
To participate in the conference call, please dial (844)
579-6824 (domestic) or (763) 488-9145 (international) and reference
the access code 95686626. The presentation will be available on the
Investors section of www.acorda.com.
A replay of the call will be available from 11:30 a.m. ET on
October 31, 2017 until 2:59 p.m. ET on November 30, 2017. To access
the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406
(international) and reference the access code 95686626. The
archived webcast will be available in the Investor Relations
section of the Acorda website at www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biopharmaceutical
company focused on developing therapies that restore function and
improve the lives of people with neurological disorders. Acorda has
a pipeline of novel neurological therapies addressing a range of
disorders, including Parkinson’s disease and multiple sclerosis.
Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: the ability to realize the benefits
anticipated from the Biotie and Civitas transactions, among other
reasons because acquired development programs are generally subject
to all the risks inherent in the drug development process and our
knowledge of the risks specifically relevant to acquired programs
generally improves over time; the ability to successfully integrate
Biotie’s operations into our operations; we may need to raise
additional funds to finance our operations and may not be able to
do so on acceptable terms; our ability to successfully market and
sell Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the
U.S., which will likely be materially adversely affected by the
recently announced court decision in our litigation against filers
of Abbreviated New Drug Applications to market generic versions of
Ampyra in the U.S.; the risk of unfavorable results from future
studies of Inbrija (CVT-301, levodopa inhalation powder),
tozadenant or from our other research and development programs, or
any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or
successfully market Inbrija, tozadenant, or any other products
under development; third party payers (including governmental
agencies) may not reimburse for the use of Ampyra, Inbrija or our
other products at acceptable rates or at all and may impose
restrictive prior authorization requirements that limit or block
prescriptions; the occurrence of adverse safety events with our
products; failure to maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaborator Biogen in connection therewith; competition;
failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements
could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171010005024/en/
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024